Johnson & Johnson has agreed to pay $5.5 billion [1] to settle U.S. lawsuits alleging its talc-based baby powder caused ovarian cancer.
This settlement resolves one of the most extensive product liability challenges in the company's history. By addressing thousands of claims simultaneously, the company seeks to end years of litigation regarding the safety of its talc products.
The agreement covers approximately 76,000 claims [2] filed in U.S. federal courts [3]. These lawsuits alleged that the company's baby powder contained asbestos, which plaintiffs argued led to the development of ovarian cancer [3].
Payments for the settlement are scheduled over two years. Johnson & Johnson will pay $3 billion [4] in 2027, followed by the remaining balance of $2.5 billion [5] in 2028. The total amount is equivalent to €4.839 billion [6].
The company has faced a mounting legal battle over the composition of its talcum powder. This multi-billion dollar resolution is intended to provide finality to the thousands of individual, and class-action suits that have moved through the federal court system [3].
“Johnson & Johnson has agreed to pay $5.5 billion to settle U.S. lawsuits”
This settlement allows Johnson & Johnson to quantify and cap its legal liabilities regarding talc products, moving the financial impact from unpredictable jury awards to a structured payment schedule. It reflects a broader corporate strategy to resolve legacy litigation that can otherwise depress stock value and create prolonged uncertainty for shareholders.
